TipRanks
Go Ultimate55% OFF

3-D Matrix (7777) AI Stock Analysis

JP:7777

3-D Matrix

(TSE/TYO:7777)

Select Model
Rating:65Neutral
Price Target:JPY 382.00â–²(7.61% Upside)
Action:reiterated
Date:09/15/26

The score is driven mainly by the financial turnaround (strong revenue growth and a swing to profitability plus a healthier balance sheet), but it is held back by weak cash-flow conversion and a history of cash burn. Technicals are moderately supportive in the short term, and valuation looks reasonable with a mid-teens P/E.

Positive Factors
Revenue growthRapid and accelerating revenue growth indicates expanding commercialization of the company’s medical technology across its target markets. If sustained, a larger revenue base can improve operating leverage, support investment in product adoption, and provide a stronger foundation for durable earnings growth over the next several quarters.
Negative Factors
Weak cash conversionWeak conversion of accounting profit into operating and free cash flow raises questions about the quality and repeatability of reported earnings. Continued cash generation will be important because small cash surpluses and a history of substantial burn could constrain reinvestment and increase the need for external funding.

3-D Matrix (7777) vs. iShares MSCI Japan ETF (EWJ)

-25%0%25%50%75%100%125%150%JP:7777+10.25%EWJ+15.87%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
JPY 310.35M
Dividend Yield
―
Average Volume (3M)
1.97M
Price to Earnings (P/E)
11.7
Beta (1Y)
1.79
Revenue Growth
55.91%
EPS Growth
―
Country
Japan
Employees
129
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

3-D Matrix Business Overview & Revenue Model

Company Description

3-D Matrix, Ltd. specializes in pioneering self-assembling peptide technology. Its flagship product, PuraMatrix, is an innovative self-assembling peptide hydrogel with diverse applications across medical fields, including regenerative medicine, cell...

3-D Matrix Financial Statement Overview

Summary

Income statement strength (74) shows rapid revenue scaling and a meaningful swing to operating and net profit, and the balance sheet improved (67) with sharply lower debt and higher equity. The key drag is weak cash-flow quality (41): operating/free cash flow are small versus net income and prior years show sizable burn, adding execution and earnings-quality risk.

Income Statement

74Positive

Balance Sheet

67Positive

Cash Flow

41Neutral
Financial statement breakdown
BreakdownTTMApr 2026Apr 2025Apr 2024Apr 2023Apr 2022
Income Statement
Total Revenue11.92B10.89B6.93B4.59B2.31B1.51B
Gross Profit9.48B8.57B4.42B3.09B1.29B661.01M
EBITDA2.54B4.17B-1.25B2.18B774.69M847.23M
Net Income3.69B4.16B-2.50B-255.50M-2.45B-1.89B
Balance Sheet
Total Assets9.40B9.80B6.51B5.89B5.83B5.61B
Cash, Cash Equivalents and Short-Term Investments1.69B2.83B1.58B1.36B1.17B2.85B
Total Debt600.00M600.00M2.94B4.17B4.37B3.67B
Total Liabilities2.18B3.00B4.30B5.53B5.30B4.15B
Stockholders Equity7.22B6.80B2.22B353.31M524.77M1.46B
Cash Flow
Free Cash Flow0368.89M-1.73B-1.90B-4.60B-2.92B
Operating Cash Flow0396.85M-1.71B-1.90B-4.59B-2.90B
Investing Cash Flow0-42.48M-33.30M-29.76M-81.50M-79.86M
Financing Cash Flow0786.49M2.01B2.06B2.96B4.66B

3-D Matrix Technical Analysis

Technical Analysis SentimentNegative
Last Price355.00

Price Trends

50DMA385.84Negative
100DMA372.17Negative
200DMA434.28Negative

Market Momentum

MACD-9.21Positive
RSI39.64Neutral
STOCH40.65Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7777, the sentiment is Negative. The current price of 355.00 is below the 20-day moving average (MA) of 386.70, below the 50-day MA of 385.84, and below the 200-day MA of 434.28, indicating a bearish trend. The MACD of -9.21 indicates Positive momentum. The RSI at 39.64 is Neutral, neither overbought nor oversold. The STOCH value of 40.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7777.

3-D Matrix Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:7777 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:6678JP:667882OutperformJPY 18.42B12.22―5.97%20.88%44.61%
JP:7777JP:777765NeutralJPY 45.44B11.6963.82%―55.91%―
JP:7963JP:796364NeutralJPY 8.49B10.10―2.90%9.02%8.88%
JP:6849JP:684961NeutralJPY 265.01B19.32―1.98%1.43%1.86%
JP:6523JP:652358NeutralJPY 180.17B19.535.76%2.97%3.04%-19.26%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4549JP:454950NeutralJPY 76.06B41.05―2.51%3.92%-52.01%

* Healthcare Sector Average

Performance Comparison

0%50%100%JP:7777JP:6523JP:4549JP:6678JP:6849JP:7963Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
JP:7777 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:77773-D Matrix 355.0033.0010.25%
JP:6523PHC Holdings Corp.1415.00438.8844.96%
JP:4549Eiken Chemical Co., Ltd.2307.003.990.17%
JP:6678Techno Medica Co., Ltd.2161.00335.3418.37%
JP:6849Nihon Kohden Corporation1616.50-129.90-7.44%
JP:7963Koken Ltd.1727.00-96.08-5.27%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 15, 2026